FIELD: pharmaceuticals.
SUBSTANCE: invention relates to compound N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide or its pharmaceutically acceptable salt. Pharmaceutical composition comprising said compound, cancer treatment methods, acute renal disease or condition, acquired immunodeficiency syndrome (AIDS) and a method of contraception in a male subject.
EFFECT: technical result: compound with inhibitory BET bromdomain activity was obtained.
8 cl, 354 ex, 8 tbl
Title | Year | Author | Number |
---|---|---|---|
BROMDOMAIN INHIBITORS | 2012 |
|
RU2647592C2 |
BROMODOMAIN INHIBITORS | 2017 |
|
RU2741808C2 |
PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | 2013 |
|
RU2646754C2 |
SUBSTITUTED TRICYCLIC COMPOUNDS AND METHOD OF APPLICATION | 2016 |
|
RU2744766C2 |
NEW PYRROLOPYRIMIDINE COMPOUND OR ITS SALT, PHARMACEUTICAL COMPOSITION CONTAINING IT, IN PARTICULAR, AGENT FOR PREVENTION AND / OR TREATMENT OF TUMORS AND SO ON, BASED ON INHIBITING INFLUENCE ON NAE | 2015 |
|
RU2658008C2 |
PYRIDINONE AND PYRIDAZINONE DERIVATIVES | 2012 |
|
RU2632915C2 |
BICYCLIC NITROIMIDAZOLES COVALENTLY CONNECTED TO REPLACED PHENYLOXAZOLYDINONES | 2009 |
|
RU2504547C2 |
ANTITUMOUR EFFECT ENHANCER CONTAINING PYRROLOPYRIMIDINE COMPOUND | 2016 |
|
RU2710380C1 |
PROTEIN KINASE INHIBITORS FOR ENHANCING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | 2019 |
|
RU2822216C2 |
AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | 2019 |
|
RU2801140C2 |
Authors
Dates
2018-11-02—Published
2012-12-11—Filed